Visit Our Blog
  • FDNA TELEHEALTH
  • Products
    • Face2Gene Labs
    • Face2Gene Clinic
  • About FDNA
  • News & Press
    • In The News
    • Press Releases
  • Contact
  • FDNA Insights

FDNA Insights

Categories
  • All
  • 2018
  • ACMG
  • Case Study
  • Events/Conferences
  • Face2Gene
  • Genomics
  • Pharma
  • Pharma
  • Phenotyping
  • Rare Diseases
  • Scientific Abstracts
  • Talks
  • Technology
  • Uncategorized
  • Videos
  • Webinar

Dr. Karen Gripp: Face2Gene RESEARCH for Deep Phenotyping of Novel Syndromes

April 18, 2018

By Christen Baglaneas

2018,ACMG,Face2Gene,Phenotyping,Talks,Technology,Videos

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link>

Starting in 1996, a select few clinicians began identifying a small group of patients with similar phenotypic features: Down-syndrome-like facial features, short stature, intellectual disability, cataracts and sensorineural hearing loss. Among these clinicians was Dr. Karen Gripp, who over the next two decades would become one of the namesakes for this MAF transcription factor related rare disease: Aymé-Gripp syndrome (AGS).

In her research, Dr. Gripp (the new Chief Medical Officer for FDNA) asked, “Does Aymé-Gripp syndrome have a facial phenotype that is recognizable using automated facial analysis?” Last week, she shared her investigation at the ACMG annual meeting.

Dr. Gripp used the Face2Gene RESEARCH application to create composite facial images for AGS and for Down syndrome, as well as for individuals with no suspected syndrome.

She ran the analysis twice, using new sets of cases for the Down syndrome and control cohorts for the second analysis to account for the “possibly subtle difference” in averaged facial images.

“There are twenty different images in those cohorts,” Dr. Gripp explained.

 

 

Dr. Gripp described the results provided by Face2Gene, including a multiclass comparison that reveals how well the system can successfully classify patients into the correct diagnosis based on facial analysis.

 

 

For each analysis, Face2Gene RESEARCH also provides statistics on the performance of the system.

“What you look at here is the mean accuracy for the analysis, and you have to always put that in perspective to the random chance for that particular analysis,” said Dr. Gripp.

 

 

Dr. Gripp’s use of the RESEARCH application is easily repeatable by any scientist on their “favorite syndrome.”

First, researchers should upload, to Face2Gene CLINIC, any patients (with at least one frontal facial photo) that they plan to use for research cohorts, being careful to clearly label [in the “case name” field] the study cohort that the patient should be added to, for example: “John Doe, Down Syndrome Cohort.” This makes it easier to find the relevant cases later when creating your study cohorts. If you are interested in analyzing the phenotype distribution for the disease, it is also important to thoroughly annotate a defined set of those phenotypes (present or absent) for every case. Otherwise, just a frontal facial photo for each case is sufficient for the analysis.

 

 

Once all the cases are added to Face2Gene CLINIC, you can move to the Face2Gene RESEARCH application by clicking “RESEARCH” in the top right corner of the app. There, you can create a new project, adding the cohorts you want to compare. To do this, select “add cohort,” and select the relevant cases from the list. Repeat for each cohort you want to create, making sure each cohort is roughly the same size.

“If you have a huge imbalance in the cohort size, that by itself introduces a bias,” Dr. Gripp mentioned.

Once cases are uploaded and cohorts are created, users can run their experiment with a click.

“You push the button, you get yourself a cup of coffee; it takes a little bit, literally a few minutes, for the system to run the analysis.”

When analysis is complete, the user receives an email with summary results and can look in more detail at each item. Results include the sensitivity and specificity reported as the area under the curve of the Receiver Operating Characteristic (ROC) curve, and the p-value to measure significance.

All of the charts and visualizations are easily copied for use in papers and publications by the researcher.

For Dr. Gripp, using the Face2Gene application resulted in the addition of a new syndrome within Face2Gene, paving the way for clinicians globally to better recognize the AGS phenotype in patients through use of  Face2Gene–and any researcher with an internet connection can now do the same for other diseases.

Watch the recording of the talk here.

 

More entries about 2018

Face2Gene
 

Extracting Features From Clinical Notes

DID YOU KNOW: By adding clinical features to your cases in Face2Gene, you increase the possible syndrome matches to 7,000+. NEW: Include features Read more

Face2Gene
 

2018 Year in Review

It was an exciting 2018 for FDNA, as we continued on our path to bring AI-based phenotyping technologies to clinicians, Read more

Events/Conferences
 

What to Do and See at ASHG 2018

San Diego, CA – The FDNA team is excited to be back at the American Society of Human Genetics (ASHG) Read more

2018
 

The Genomics Collaborative: How to Design the Future of Health—Together

  ThinkGenetic recently hosted a panel discussion among researchers involved in the Genomics Collaborative, an FDNA initiative connecting researchers, clinicians, Read more

ACMG
 

Dr. Christine Stanley: Face2Gene LABS at WuXi NextCODE: Phenotyping for Improved Variant Prioritization

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link> Read more

ACMG
 

Dr. John Carey: Delineating Genetic Syndromes and Next-Generation Phenotyping

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this Read more

ACMG
 

Dr. Karen Gripp: Face2Gene RESEARCH for Deep Phenotyping of Novel Syndromes

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this Read more

  • Contact Us
  • Privacy Policy
  • Terms of Use

Signup for News


* These fields are required.

© 2011-2021 FDNA INC. www.FDNA.com. All rights reserved.

Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.